First-in-human study to assess the safety, tolerability, pharmacokinetics and immunogenicity of DS002, an anti-nerve growth factor monoclonal antibody

Purpose: To evaluate the safety, tolerability, pharmacokinetics and immunogenicity of DS002 injection, an anti-nerve growth factor (anti-NGF) monoclonal antibody for treating pain conditions, in healthy Chinese subjects. Methods: This study was a single-center, randomized, double-blind, single-dose...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Tingting, Cao, Bei, Huang, Lei, Yang, Yuanxun, Geng, Yan, Xie, Pinhao, Zhao, Yu, Lin, Hui, Wang, Kun, Wang, Chunhe, Sun, Runbin, Li, Juan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9790963/
https://www.ncbi.nlm.nih.gov/pubmed/36578547
http://dx.doi.org/10.3389/fphar.2022.1075309

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9790963/
https://www.ncbi.nlm.nih.gov/pubmed/36578547
http://dx.doi.org/10.3389/fphar.2022.1075309

Ejemplares similares